KemPharm Inc. (NASDAQ:KMPH)’s share price dropped 2.1% during mid-day trading on Monday . The stock traded as low as $3.97 and last traded at $4.11, with a volume of 51,198 shares trading hands. The stock had previously closed at $4.20.

KMPH has been the topic of several research reports. Royal Bank Of Canada cut their price objective on shares of KemPharm from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, May 6th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of KemPharm in a research note on Wednesday, June 8th. Zacks Investment Research downgraded shares of KemPharm from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. Finally, Canaccord Genuity restated a “buy” rating on shares of KemPharm in a research note on Tuesday, May 3rd. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $26.80.

The company has a 50 day moving average of $5.05 and a 200-day moving average of $12.00. The company’s market capitalization is $60.91 million.

KemPharm (NASDAQ:KMPH) last issued its quarterly earnings data on Thursday, May 12th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.26. Analysts predict that KemPharm Inc. will post ($2.79) EPS for the current fiscal year.

An institutional investor recently raised its position in KemPharm stock. EAM Investors LLC increased its stake in KemPharm Inc. (NASDAQ:KMPH) by 0.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,253 shares of the specialty pharmaceutical company’s stock after buying an additional 240 shares during the period. EAM Investors LLC owned approximately 0.42% of KemPharm worth $1,216,000 at the end of the most recent quarter.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. It uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs by chemically attaching one or more molecules, referred to as ligands, to the parent drug.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.